1887
Rapid communication Open Access
Like 0

Abstract

Interim results from Canada's Sentinel Practitioner Surveillance Network show that during a season characterised by early co-circulation of influenza A and B viruses, the 2019/20 influenza vaccine has provided substantial protection against medically-attended influenza illness. Adjusted VE overall was 58% (95% confidence interval (CI): 47 to 66): 44% (95% CI: 26 to 58) for A(H1N1)pdm09, 62% (95% CI: 37 to 77) for A(H3N2) and 69% (95% CI: 57 to 77) for influenza B viruses, predominantly B/Victoria lineage.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.7.2000103
2020-02-20
2020-05-30
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.7.2000103
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/7/eurosurv-25-7-1.html?itemId=/content/10.2807/1560-7917.ES.2020.25.7.2000103&mimeType=html&fmt=ahah

References

  1. Public Health Agency of Canada (PHAC). Weekly influenza reports 2019-20 season. FluWatch report: January 26 to February 1, 2020 (Week 5). Ottawa: PHAC. [Accessed 16 Feb 2020]. Available from: https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html
  2. European Centre for Disease Prevention and Control (ECDC). World Health Organization (WHO) Regional office for Europe. Flu News Europe, Joint ECDC–WHO weekly influenza update, week 05/2020. [Accessed 16 Feb 2020]. Available from: http://flunewseurope.org/Archives
  3. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization, December 2019. Stockholm: ECDC. [Accessed 1 Feb 2020]. Available from: https://www.ecdc.europa.eu/en/publications-data/influenza-virus-characterisation-december-2019
  4. Centers for Disease Control and Prevention (CDC). FluView: Weekly influenza surveillance report. 2019-2020 influenza season week 5 ending February 1, 2020. Atlanta: CDC. [Accessed 16 Feb 2020]. Available from: https://www.cdc.gov/flu/weekly/pastreports.htm
  5. World Health Organization (WHO). Influenza updates for 2019-2020 season. Geneva: WHO. [Accessed 1 Feb 2020]. Available from: https://www.who.int/influenza/surveillance_monitoring/updates/en/
  6. Canadian Sentinel Practitioner Surveillance Network (SPSN). Influenza vaccine effectiveness estimates % (95% CI), 2004-05 to 2018-19 seasons. Vancouver: British Columbia Centre for Disease Control. [Accessed 1 Feb 2020]. Available from: http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Influenza%20and%20Respiratory/SPSN_VE_By_Year_Table.pdf
  7. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669-683. https://doi:  https://doi.org/10.1586/eri.11.51  PMID: 21692672.
  8. Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019. Euro Surveill. 2019;24(4):1900055.  https://doi.org/10.2807/1560-7917.ES.2019.24.4.1900055  PMID: 30696523 
  9. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO. [Accessed 1 Feb 2020]. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/en/
  10. Worldwide Influenza Centre, Francis Crick Institute. September 2019 interim report. London: Francis Crick Institute. [Accessed 1 Feb 2020]. Available from: https://www.crick.ac.uk/partnerships/worldwide-influenza-centre/annual-and-interim-reports
  11. Public Health Agency of Canada (PHAC). How healthy are Canadians? A trend analysis of the health of Canadians from a healthy living and chronic disease perspective. Ottawa: PHAC; 2017. [Accessed 1 Feb 2020]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/how-healthy-canadians.html
  12. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015-2016 season in Canada. J Infect Dis. 2017;216(12):1487-500.  https://doi.org/10.1093/infdis/jix526  PMID: 29029166 
  13. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season. J Infect Dis. 2015;212(5):726-39.  https://doi.org/10.1093/infdis/jiv177  PMID: 25784728 
  14. Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, et al. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. J Clin Invest. 2018;128(11):4992-6.  https://doi.org/10.1172/JCI122895  PMID: 30188868 
  15. Rudneva I, Ignatieva A, Timofeeva T, Shilov A, Kushch A, Masalova O, et al. Escape mutants of pandemic influenza A/H1N1 2009 virus: variations in antigenic specificity and receptor affinity of the hemagglutinin. Virus Res. 2012;166(1-2):61-7.  https://doi.org/10.1016/j.virusres.2012.03.003  PMID: 22459010 
  16. Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE Jr, Wilson IA, et al. Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog. 2012;8(12):e1003067.  https://doi.org/10.1371/journal.ppat.1003067  PMID: 23236279 
  17. Yasugi M, Kubota-Koketsu R, Yamashita A, Kawashita N, Du A, Misaki R, et al. Emerging antigenic variants at the antigenic site Sb in pandemic A(H1N1)2009 influenza virus in Japan detected by a human monoclonal antibody. PLoS One. 2013;8(10):e77892.  https://doi.org/10.1371/journal.pone.0077892  PMID: 24147093 
  18. Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Vaccine effectiveness against lineage-matched and-mismatched influenza B viruses across 8 seasons in Canada, 2010-2011 to 2017-2018. Clin Infect Dis. 2019;68(10):1754-7.  https://doi.org/10.1093/cid/ciy876  PMID: 30312364 
  19. Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Age-related differences in influenza B infection by lineage in a community-based sentinel system, 2010-2011 to 2015-2016. J Infect Dis. 2017;216(6):697-702.  https://doi.org/10.1093/infdis/jix393  PMID: 28934439 
  20. Cowling BJ, Wu P, Lo JYC, Chan KH, Chan ELY, Fang VJ, et al. Population-based pediatric hospitalization burden of lineage-specific influenza B in Hong Kong, 2004-2014. Clin Infect Dis. 2017;65(2):300-7.  https://doi.org/10.1093/cid/cix312  PMID: 28387792 
  21. Statistics Canada. Table 17-10-0005-01: Population estimates on July 1st, by age and sex. Ottawa: Statistics Canada. [Accessed 5 Feb 2020]. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501
  22. Gaglani M, Vasudevan A, Raiyani C, Murthy K, Chen W, Reis M, et al. Effectiveness of trivalent and quadrivalent inactivated vaccines against influenza B in the United States, 2011-2012 to 2016-2017. Clin Infect Dis. 2020;ciaa102.  https://doi.org/10.1093/cid/ciaa102  PMID: 32006430 
  23. Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, Sabaiduc S, et al. Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata. Pediatr Infect Dis J. 2011;30(10):833-9.  https://doi.org/10.1097/INF.0b013e31822db4dc  PMID: 21857263 
  24. Skowronski DM, Hamelin ME, Janjua NZ, De Serres G, Gardy JL, Rhéaume C, et al. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One. 2012;7(6):e38929.  https://doi.org/10.1371/journal.pone.0038929  PMID: 22745690 
  25. Skowronski DM, Sabaiduc S, Leir S, Rose C, Zou M, Murti M, et al. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV). Euro Surveill. 2019;24(46):1900585.  https://doi.org/10.2807/1560-7917.ES.2019.24.46.1900585  PMID: 31771709 
  26. Jorquera PA, Mishin VP, Chesnokov A, Nguyen HT, Mann B, Garten R, et al. Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018. Sci Rep. 2019;9(1):2676.  https://doi.org/10.1038/s41598-019-39276-1  PMID: 30804469 
  27. Epperson S, Davis CT, Brammer L, Abd Elal AI, Ajayi N, Barnes J, et al. Update: Influenza activity – United States and worldwide, May 19 – September 28, 2019, and composition of the 2020 southern hemisphere influenza vaccine. MMWR Morb Mortal Wkly Rep. 2019;68(40):880-4.  https://doi.org/10.15585/mmwr.mm6840a3  PMID: 31600182 
  28. Kissling E, Pozo F, Buda S, Vilcu A-M, Gherasim A, Brytting M, et al. I-Move Primary Care Study Team. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort. Euro Surveill. 2019;24(48):1900604.  https://doi.org/10.2807/1560-7917.ES.2019.24.48.1900604  PMID: 31796152 
  29. Kelvin AA, Zambon M. Influenza imprinting in childhood and the influence on vaccine response later in life. Euro Surveill. 2019;24(48):1900720.  https://doi.org/10.2807/1560-7917.ES.2019.24.48.1900720  PMID: 31796156 
/content/10.2807/1560-7917.ES.2020.25.7.2000103
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error